Evangelos T.
- Country
- Greece
- Department
- 300001: Clinical Therapeutics
Research Overview
- Evaluation of Belantamab Monotherapy and Combination Regimens in Patients with Multiple Myeloma: Safety and Clinical Activity Assessment
- Phase 3 Randomized Study of JNJ‑79635322 Versus Teclistamab in Relapsed or Refractory Multiple Myeloma After 1–3 Prior Lines Including Anti‑CD38 Antibody and Lenalidomide
- Efficacy and Safety Evaluation of Selinexor and Ruxolitinib in Treatment-Naïve Myelofibrosis Patients: A Phase 1/3 Clinical Trial
Data & Insights
Has run more than one trial at 178 of 310 partner sites.
Specializations
Multiple Myeloma Treatment
This investigator specializes in novel therapeutic approaches for multiple myeloma, with particular focus on both newly diagnosed and relapsed/refractory cases. Their research encompasses innovative combination therapies involving daratumumab, bortezomib, and lenalidomide.
- Stem Cell Transplantation Protocols
- CAR T-Cell Therapy Applications
- Maintenance Therapy Strategies
Special attention is given to patients with extramedullary disease and those with severe renal impairment.
Hematologic Malignancies
The investigator conducts research in various blood disorders, including primary plasma cell leukemia and essential thrombocythaemia. Their work involves evaluating novel treatment protocols and combination therapies.
- Immunotherapy Approaches
- Targeted Molecular Therapies
- Treatment Response Monitoring
Research includes investigating new therapeutic options for myelofibrosis and immune thrombocytopenia.
Therapeutic Innovation
Focus areas include gene-modified T cell therapy and novel drug combinations. The investigator studies advanced treatment approaches for various hematologic conditions.
- Long-term Treatment Outcomes
- Drug Resistance Management
- Minimal Residual Disease Assessment
Expertise extends to monitoring treatment efficacy and safety in various patient populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.